Last reviewed · How we verify
Tremelimumab (Regimen 2)
Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses. Used for Unresectable or metastatic melanoma (in combination with durvalumab), Hepatocellular carcinoma (in combination with durvalumab).
At a glance
| Generic name | Tremelimumab (Regimen 2) |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | CTLA-4 inhibitor |
| Target | CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tremelimumab binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a checkpoint protein that normally suppresses T cell activation. By blocking CTLA-4, the antibody prevents tumor cells from turning off immune responses, allowing T cells to proliferate and attack cancer cells more effectively. This mechanism is particularly potent when combined with other immunotherapies such as PD-L1 inhibitors.
Approved indications
- Unresectable or metastatic melanoma (in combination with durvalumab)
- Hepatocellular carcinoma (in combination with durvalumab)
Common side effects
- Fatigue
- Diarrhea
- Immune-related colitis
- Hepatotoxicity
- Rash
- Pneumonitis
Key clinical trials
- IIT2025-03-YANG-LIFT-HCC (PHASE2)
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (PHASE3)
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma (PHASE2)
- BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma (PHASE1, PHASE2)
- Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma (PHASE2, PHASE3)
- A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (PHASE3)
- PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer (PHASE1, PHASE2)
- Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tremelimumab (Regimen 2) CI brief — competitive landscape report
- Tremelimumab (Regimen 2) updates RSS · CI watch RSS
- AstraZeneca portfolio CI